

# **Choroidal Neovascularization - Pipeline Review, H2 2019**

<https://marketpublishers.com/r/C7531403DD1EN.html>

Date: November 2019

Pages: 57

Price: US\$ 2,000.00 (Single User License)

ID: C7531403DD1EN

## **Abstracts**

Choroidal Neovascularization - Pipeline Review, H2 2019

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization - Pipeline Review, H2 2019, provides an overview of the Choroidal Neovascularization (Ophthalmology) pipeline landscape.

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid. Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes anti-VEGF agents, laser photocoagulation and photodynamic therapy.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Choroidal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under

Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Choroidal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Choroidal Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Choroidal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization (Ophthalmology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Choroidal Neovascularization (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Choroidal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Choroidal Neovascularization - Overview
- Choroidal Neovascularization - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Choroidal Neovascularization - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Choroidal Neovascularization - Companies Involved in Therapeutics Development
- 3SBio Inc
- Allysta Pharmaceuticals Inc
- AsclepiX Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Formycon AG
- Iconic Therapeutics Inc
- Isarna Therapeutics GmbH
- Lupin Ltd
- Mabion SA
- NovelMed Therapeutics Inc
- Oceanyx Pharmaceuticals Inc
- Promedior Inc
- Protheragen Inc
- Yantai RC-Pharmaceutical Co Ltd
- Choroidal Neovascularization - Drug Profiles
- ACX-107 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- afibercept biosimilar - Drug Profile
- Product Description
- Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allo-Aca - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Apratoxin S4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

faricimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICON-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISTH-0036 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit VEGF for Ophthalmology and Oncology - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
NM-9405 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
PRM-167 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
ranibizumab biosimilar - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
RC-28 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Small Molecule for Choroidal Neovascularization and Inflammation - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Choroidal Neovascularization - Dormant Projects  
Choroidal Neovascularization - Discontinued Products  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Choroidal Neovascularization, H2 2019  
Number of Products under Development by Companies, H2 2019  
Number of Products under Development by Universities/Institutes, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Universities/Institutes, H2 2019  
Number of Products by Stage and Target, H2 2019  
Number of Products by Stage and Mechanism of Action, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Choroidal Neovascularization - Pipeline by 3SBio Inc, H2 2019  
Choroidal Neovascularization - Pipeline by Allysta Pharmaceuticals Inc, H2 2019  
Choroidal Neovascularization - Pipeline by AsclepiX Therapeutics Inc, H2 2019  
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019  
Choroidal Neovascularization - Pipeline by Formycon AG, H2 2019  
Choroidal Neovascularization - Pipeline by Iconic Therapeutics Inc, H2 2019  
Choroidal Neovascularization - Pipeline by Isarna Therapeutics GmbH, H2 2019  
Choroidal Neovascularization - Pipeline by Lupin Ltd, H2 2019  
Choroidal Neovascularization - Pipeline by Mabion SA, H2 2019  
Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H2 2019  
Choroidal Neovascularization - Pipeline by Oceanyx Pharmaceuticals Inc, H2 2019  
Choroidal Neovascularization - Pipeline by Promedior Inc, H2 2019  
Choroidal Neovascularization - Pipeline by Protheragen Inc, H2 2019  
Choroidal Neovascularization - Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019  
Choroidal Neovascularization - Dormant Projects, H2 2019  
Choroidal Neovascularization - Dormant Projects, H2 2019 (Contd..1), H2 2019  
Choroidal Neovascularization - Discontinued Products, H2 2019



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Choroidal Neovascularization, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

3SBio Inc

Allysta Pharmaceuticals Inc

AsclepiX Therapeutics Inc

F. Hoffmann-La Roche Ltd

Formycon AG

Iconic Therapeutics Inc

Isarna Therapeutics GmbH

Lupin Ltd

Mabion SA

NovelMed Therapeutics Inc

Oceanyx Pharmaceuticals Inc

Promedior Inc

Protheragen Inc

Yantai RC-Pharmaceutical Co Ltd

## I would like to order

Product name: Choroidal Neovascularization - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C7531403DD1EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7531403DD1EN.html>